Amanda Lu
Yale University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Amanda Lu.
Journal of Clinical Oncology | 2016
Cayce Nawaf; Amanda Lu; James Rosoff; Jeffrey C. Weinreb; Peter G. Schulam; Peter A. Humphrey; Angelique Levi; Preston Sprenkle
90 Background: Patients with an elevated PSA but negative prostate biopsy present a diagnostic and management dilemma. We evaluated the capability of multi-parametric (MP) MRI and MRI-USG Fusion prostate biopsy to detect clinically significant (CS) prostate cancer in men who have had a prior negative 12-core standard biopsy. Methods: Between 12/2012 and 06/2015, 374 men with an indication for prostate biopsy underwent pre-biopsy mpMRI followed by 12-core standard trans-rectal mapping biopsy (Mbx) and MRI-Ultrasound fusion targeted biopsy (Tbx) of lesions identified on mpMRI. The combination of Mbx and Tbx, when both occurred, constitutes a fusion biopsy (Fbx). Men who underwent both Mbx with or without Tbx using the Artemis/Pro-Fuse system with a previous biopsy but no diagnosis of prostate cancer were included. Patients without a lesion on MRI underwent Mbx only. Maximum Gleason scores (GS) was assigned on a per patient basis with Mbx GS available for all patients in the cohort and Tbx GS available only ...
Journal of Clinical Oncology | 2016
Cayce Nawaf; James Rosoff; Amanda Lu; Jeffrey C. Weinreb; Peter A. Humphrey; Angelique Levi; Peter G. Schulam; Preston Sprenkle
88 Background: Appropriate risk stratification of men on active surveillance for prostate cancer is essential to identify men in whom it is safe to take this deferred treatment approach. This study evaluates upstaging rates using MRI-US fusion targeted biopsy in men who have had a prior positive standard 12-core biopsy. Methods: Between 12/2012 and 06/2015, 374 men with an indication for prostate biopsy underwent pre-biopsy mpMRI followed by 12-core standard trans-rectal mapping biopsy (Mbx) and MRI-Ultrasound fusion targeted biopsy (Tbx) of lesions identified on mpMRI. The combination of Mbx and Tbx, when both occurred, constitutes a fusion biopsy (Fbx). Men who underwent both Mbx with or without Tbx using the Artemis/Pro-Fuse system with a previous non-MRI-guided biopsy and a diagnosis of prior Gleason 6 prostate cancer were included. Patients without a lesion on MRI underwent Mbx only. Maximum Gleason scores (GS) were assigned on a per patient basis with Mbx GS available for all patients in the cohort ...
The Journal of Urology | 2018
Amanda Lu; Kamyar Ghabili Amirkhiz; Kevin Tri Nguyen; Walter Hsiang; Michael Leapman
The Journal of Urology | 2018
Amanda Lu; Kamyar Ghabili Amirkhiz; Kevin Tri Nguyen; Michael Leapman; Preston Sprenkle
The Journal of Urology | 2018
Kevin Tri Nguyen; Adam Nolte; Oriyomi Alimi; Walter Hsiang; Jamil S. Syed; Alfredo Suarez-Sarmiento; Amanda Lu; Kamyar Ghabili; Brian Shuch; Michael Leapman
The Journal of Urology | 2018
Kevin Tri Nguyen; Walter Hsiang; Jamil S. Syed; Adam Nolte; Amanda Lu; Alfredo Suarez-Sarmiento; Kamyar Ghabili; Brian Shuch; Michael Leapman
The Journal of Urology | 2018
Walter Hsiang; Kamyar Ghabili; Amanda Lu; Jamil S. Syed; Kevin Tri Nguyen; Alfredo Suarez-Sarmiento; Michael Leapman; Preston Sprenkle
Journal of Clinical Oncology | 2018
Kamyar Ghabili; Kevin A. Nguyen; Amanda Lu; Walter Hsiang; Brian Shuch; Michael Leapman
Journal of Clinical Oncology | 2018
Amanda Lu; Kamyar Ghabili; Kevin A. Nguyen; Preston Sprenkle
Journal of Clinical Oncology | 2018
Amanda Lu; Kamyar Ghabili; Kevin A. Nguyen; Michael Leapman; Preston Sprenkle